XML 58 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Tables)
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table illustrates information about segment revenues, significant segment expenses, and segment net income (loss) for the three and nine months ended September 30, 2025 and 2024 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Revenues$159,395 $117,085 $468,282 $319,178 
Less1:
Cost of product sales2,187 3,211 9,553 6,175 
Research and development
Berotralstat2,575 2,954 9,214 10,504 
BCX177257,574 1,154 13,346 6,591 
Avoralstat1,800 2,104 7,584 4,960 
Factor D Program35 1,193 454 7,299 
Research, discovery and preclinical programs5,457 3,309 11,641 8,325 
Compensation and related personnel costs13,313 14,257 38,025 42,630 
Stock-based compensation6,520 8,530 24,374 20,923 
Other non-program specific and indirect costs7,329 7,580 20,621 23,965 
Selling, general and administrative83,014 65,101 252,866 185,841 
Interest income(2,238)(3,591)(7,778)(11,176)
Interest expense19,661 24,828 64,737 74,067 
Foreign currency (gains) losses, net(35)(98)27 37 
Loss on extinguishment of debt2,740 — 6,911 — 
Other income(2,667)— (2,667)— 
Income tax (benefit) expense(769)586 1,358 1,123 
Segment net income (loss)12,899 (14,033)18,016 (62,086)
Reconciliation of segment profit or loss:
Adjustments and reconciling items— — — — 
Consolidated net income (loss)$12,899 $(14,033)$18,016 $(62,086)
1 The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.